Chong Kun Dang Pharmaceutical Corp.
185750.KSFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
1,190
Cost of Revenue
790
Gross Profit
399
Gross Margin
33.6%
Operating Income
75
Operating Margin
6.3%
Net Income
82
Net Margin
6.9%
EPS (Basic)
$6.00
EPS (Diluted)
$6.00
EBITDA
113
EBITDA Margin
9.5%
2023
12/31/2023
Revenue
1,252
Cost of Revenue
755
Gross Profit
497
Gross Margin
39.7%
Operating Income
185
Operating Margin
14.8%
Net Income
159
Net Margin
12.7%
EPS (Basic)
$13.00
EPS (Diluted)
$13.00
EBITDA
216
EBITDA Margin
17.2%
2022
12/31/2022
Revenue
1,116
Cost of Revenue
709
Gross Profit
407
Gross Margin
36.5%
Operating Income
82
Operating Margin
7.4%
Net Income
61
Net Margin
5.4%
EPS (Basic)
$5.00
EPS (Diluted)
$5.00
EBITDA
103
EBITDA Margin
9.2%
2021
12/31/2021
Revenue
1,008
Cost of Revenue
636
Gross Profit
372
Gross Margin
36.9%
Operating Income
71
Operating Margin
7.1%
Net Income
32
Net Margin
3.2%
EPS (Basic)
$3.00
EPS (Diluted)
$3.00
EBITDA
84
EBITDA Margin
8.4%
2020
12/31/2020
Revenue
977
Cost of Revenue
610
Gross Profit
367
Gross Margin
37.5%
Operating Income
93
Operating Margin
9.5%
Net Income
69
Net Margin
7.0%
EPS (Basic)
$5.00
EPS (Diluted)
$5.00
EBITDA
112
EBITDA Margin
11.5%